<PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">39003200</PMID><DateRevised><Year>2024</Year><Month>07</Month><Day>13</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1471-499X</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2024</Year><Month>Jul</Month><Day>13</Day></PubDate></JournalIssue><Title>Trends in molecular medicine</Title><ISOAbbreviation>Trends Mol Med</ISOAbbreviation></Journal><ArticleTitle>Virus as the cause of type 1 diabetes.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">S1471-4914(24)00183-7</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.molmed.2024.06.011</ELocationID><Abstract><AbstractText>Type 1 diabetes (T1D), a severe disease requiring intensive insulin treatment, carries an increased risk for complications and reduced lifespan. Certain viruses have been implicated in T1D's etiology, with 'live', replicating enteroviruses (EVs) recently found in the pancreas at diagnosis. This discovery prompted a trial to slow down disease progression using antiviral drugs. A 6-month treatment combining pleconaril and ribavirin in new-onset T1D patients preserved residual insulin production after 1 year, unlike placebo. The results support the theory that viruses may cause T1D in genetically susceptible individuals. A low-grade, persistent viral infection may initiate a cascade of pathogenic mechanisms initially involving the innate immune system, inducing β-cell stress and neoantigen release, leading to autoimmunity, and eventually the destruction of insulin-producing β-cells.</AbstractText><CopyrightInformation>Copyright © 2024 The Author. Published by Elsevier Ltd.. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Dahl-Jørgensen</LastName><ForeName>Knut</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Pediatric Department, Oslo University Hospital and Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway. Electronic address: knut.dahl-jorgensen@medisin.uio.no.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>07</Month><Day>13</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Trends Mol Med</MedlineTA><NlmUniqueID>100966035</NlmUniqueID><ISSNLinking>1471-4914</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">antivirals</Keyword><Keyword MajorTopicYN="N">enterovirus</Keyword><Keyword MajorTopicYN="N">pathogenesis</Keyword><Keyword MajorTopicYN="N">type 1 diabetes</Keyword><Keyword MajorTopicYN="N">vaccines</Keyword></KeywordList><CoiStatement>Declaration of interests The author has no conflicts of interest to declare.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>4</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>6</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>6</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>7</Month><Day>14</Day><Hour>2</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>7</Month><Day>14</Day><Hour>2</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>7</Month><Day>13</Day><Hour>21</Hour><Minute>59</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39003200</ArticleId><ArticleId IdType="doi">10.1016/j.molmed.2024.06.011</ArticleId><ArticleId IdType="pii">S1471-4914(24)00183-7</ArticleId></ArticleIdList></PubmedData></PubmedArticle>